Therapy News and Research

RSS

RA drug effective against Entamoeba histolytica

Research by a collaborative group of scientists from UC San Diego School of Medicine, UC San Francisco and Wake Forest School of Medicine has led to identification of an existing drug that is effective against Entamoeba histolytica. This parasite causes amebic dysentery and liver abscesses and results in the death of more than 70,000 people worldwide each year.

21 May 2012

Experimental bariatric surgery can lower blood sugar levels in rats with type 1 diabetes

For the first time, scientists at the Toronto General Hospital Research Institute have shown that an experimental bariatric surgery can lower blood sugar levels in rats with type 1 diabetes.

21 May 2012

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis.

21 May 2012

Auranofin effective against amoebas in lab and animal studies

A team of researchers from UCSF and UC San Diego has identified an approved arthritis drug that is effective against amoebas in lab and animal studies, suggesting it could offer a low-dose, low cost treatment for the amoebic infections that cause human dysentery throughout the world.

21 May 2012

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led study presented to the American Urological Association.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

The Stem Cells and Cancer Research Group headed by Dr H-ctor G. Palmer at the Vall d'Hebr-n Institute of Oncology (VHIO) has identified the molecular mechanisms that determine patients' response to certain drugs used in clinical trials for colon cancer treatment. The study led by VHIO also benefited from the collaboration with Professor Alberto Mu-oz-s laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cient-ficas.

21 May 2012

Panobinostat able to target and destroy triple negative breast cancer

The histone de-acetylase (HDAC) inhibitor panobinostat is able to target and destroy triple negative breast cancer, reveals a new study published in BioMed Central's open access journal Breast Cancer Research.

21 May 2012

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric pH.

21 May 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120.

19 May 2012

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012

Positive results from CardioKinetix Parachute system study on heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device, a Percutaneous Ventricular Restoration (PVR) therapy for patients with ischemic heart failure.

19 May 2012

AACN to honor Detroit nurse with Flame of Excellence Award

The American Association of Critical-Care Nurses (AACN) will present the Flame of Excellence Award to Margaret L. "Meg" Campbell, Ph.D., RN, FAAN, a nationally known expert in hospital-based palliative care and end-of-life issues.

19 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

UK-led technologies set to transform treatments on the NHS

Video games, pioneering gene therapies and new medical devices are set to transform treatments on the NHS, with support from the Department of Health and the Wellcome Trust.

19 May 2012

Study focuses on role of the brain and mind in chronic and complex pain disorders

Training the brain to reduce pain could be a promising approach for treating phantom limb pain and complex regional pain syndrome, according to an internationally known neuroscience researcher speaking today at the American Pain Society's Annual Scientific Meeting.

19 May 2012

Promising updates in quest for early detection and treatments for lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to note promising updates in researchers' quest for early detection and treatments for lung cancer during May, Lung Cancer Hope Month.

18 May 2012

Cautious optimism over prevalence of PTSD

A decade after the start of the wars in Afghanistan and Iraq, studies have shown that the incidence of post-traumatic stress disorder (PTSD) among troops is surprisingly low, and a Harvard researcher credits the drop, in part, to new efforts by the Army to prevent PTSD, and to ensure those who do develop the disorder receive the best treatment available.

18 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Health Canada approves Osiris’ Prochymal to treat acute GvHD in children

Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

18 May 2012

Therapy News and Research

RA drug effective against Entamoeba histolytica

Experimental bariatric surgery can lower blood sugar levels in rats with type 1 diabetes

Hypertonic saline does not reduce rate of pulmonary exacerbations in young children with CF

Auranofin effective against amoebas in lab and animal studies

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

Panobinostat able to target and destroy triple negative breast cancer

POZEN presents data from PA32540 Phase 1 gastric acid reduction study at DDW 2012

Ceregene announces new data from CERE-120 clinical trial on Parkinson's

Final results from C3BS-CQR-1 Phase II trial on heart failure

Positive results from CardioKinetix Parachute system study on heart failure

AACN to honor Detroit nurse with Flame of Excellence Award

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

UK-led technologies set to transform treatments on the NHS

Study focuses on role of the brain and mind in chronic and complex pain disorders

Promising updates in quest for early detection and treatments for lung cancer

Cautious optimism over prevalence of PTSD

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Health Canada approves Osiris’ Prochymal to treat acute GvHD in children

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News